Shots: Genmab to receive $750M as up front and is eligible to receive ~$3.15B as development, regulatory & commercial milestones for all programs along with royalties (22% – 26%) on sales for epcoritamab (ex- US & Japan). The collaboration includes development and commercialization of the three bispecific Ab therapeutic candidates The parties equally share pre-tax […]Read More
